Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites - 2Figure out How to Assess the Unwavering quality of SUVs for Seniors
- 3Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- 4The Best Design Bloggers for Style Motivation
- 5Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- Make your choice for the music application with the most amicable connection point!
- Tech Patterns: Contraptions That Will Shape What's in store
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- Beating Wellbeing Difficulties: Individual Victories in Health
- RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
